Oligometastatic prostate cancer comprises a wide spectrum of conditions, ranging from de novo oligometastatic cancer at diagnosis to oligometastatic castration-resistant disease, which are distinct entities in terms of biology and prognosis. In order to clarify and standardize the clinical role of ablative radiotherapy in oligometastatic prostate cancer, the Italian Association of Radiotherapy and Clinical Oncology (AIRO) formed an expert panel to review the current literature and develop a formal consensus. Oligometastatic prostate cancer was defined as the presence of up to three metastatic lesions involving bones or nodes outside pelvis. Thereafter, four clinical scenarios were explored: metastatic castration-sensitive disease at diagnosis and after primary treatment, and metastatic castration-resistant disease at diagnosis and during treatment, where the role of ablative radiotherapy was defined either in conjunction with systemic therapy or as the only treatment in selected cases. This paper summarizes the current literature about these issues and the proposed recommendations.

D'Angelillo, R., Francolini, G., Ingrosso, G., Ravo, V., Triggiani, L., Magli, A., et al. (2019). Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 138, 24-28 [10.1016/j.critrevonc.2019.03.014].

Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO)

Arcangeli, S;
2019

Abstract

Oligometastatic prostate cancer comprises a wide spectrum of conditions, ranging from de novo oligometastatic cancer at diagnosis to oligometastatic castration-resistant disease, which are distinct entities in terms of biology and prognosis. In order to clarify and standardize the clinical role of ablative radiotherapy in oligometastatic prostate cancer, the Italian Association of Radiotherapy and Clinical Oncology (AIRO) formed an expert panel to review the current literature and develop a formal consensus. Oligometastatic prostate cancer was defined as the presence of up to three metastatic lesions involving bones or nodes outside pelvis. Thereafter, four clinical scenarios were explored: metastatic castration-sensitive disease at diagnosis and after primary treatment, and metastatic castration-resistant disease at diagnosis and during treatment, where the role of ablative radiotherapy was defined either in conjunction with systemic therapy or as the only treatment in selected cases. This paper summarizes the current literature about these issues and the proposed recommendations.
Articolo in rivista - Review Essay
Ablative radiotherapy; Oligometastatic; Prostate cancer; SABR; SBRT; Stereotactic radiotherapy;
Ablative radiotherapy; Oligometastatic; Prostate cancer; SABR; SBRT; Stereotactic radiotherapy; Hematology; Oncology
English
2019
138
24
28
reserved
D'Angelillo, R., Francolini, G., Ingrosso, G., Ravo, V., Triggiani, L., Magli, A., et al. (2019). Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 138, 24-28 [10.1016/j.critrevonc.2019.03.014].
File in questo prodotto:
File Dimensione Formato  
CROH_2019.pdf

Solo gestori archivio

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 590.34 kB
Formato Adobe PDF
590.34 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/227665
Citazioni
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 31
Social impact